MX2022010794A - Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). - Google Patents

Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).

Info

Publication number
MX2022010794A
MX2022010794A MX2022010794A MX2022010794A MX2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A MX 2022010794 A MX2022010794 A MX 2022010794A
Authority
MX
Mexico
Prior art keywords
taar1
crystalline forms
salts
taar1 agonist
agonist
Prior art date
Application number
MX2022010794A
Other languages
English (en)
Inventor
Frank Stowasser
Urs Schwitter
Trussardi, (Fallecido) René
Kirsten Andrea Graeser
Florence Nicole Antoinette Tixeront
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022010794A publication Critical patent/MX2022010794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas cristalinas y amorfas de sales farmacéuticamente aceptables del agonista de TAAR1 5-etil-4-metil-N-[4-[(2S) morfolin-2-il]fenil]-1H-pirazol-3-carbox amida. También se describen composiciones farmacéuticas adecuadas para la administración a un mamífero que incluyen el agonista de TAAR1, y métodos para el uso del agonista de TAAR1, solo y en combinación con otros compuestos, para tratar enfermedades o afecciones asociadas con la actividad de TAAR1.
MX2022010794A 2020-03-19 2021-03-17 Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). MX2022010794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Publications (1)

Publication Number Publication Date
MX2022010794A true MX2022010794A (es) 2022-09-27

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010794A MX2022010794A (es) 2020-03-19 2021-03-17 Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).

Country Status (12)

Country Link
US (1) US20230120311A1 (es)
EP (1) EP4121428A1 (es)
JP (1) JP2023517729A (es)
KR (1) KR20220155575A (es)
CN (1) CN115279752A (es)
AU (1) AU2021238632A1 (es)
BR (1) BR112022016746A2 (es)
CA (1) CA3166331A1 (es)
IL (1) IL294301A (es)
MX (1) MX2022010794A (es)
TW (1) TW202140466A (es)
WO (1) WO2021185878A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033459A1 (en) * 2022-08-12 2024-02-15 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
SG10201913878YA (en) 2016-03-17 2020-03-30 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Also Published As

Publication number Publication date
JP2023517729A (ja) 2023-04-26
US20230120311A1 (en) 2023-04-20
CN115279752A (zh) 2022-11-01
BR112022016746A2 (pt) 2022-10-11
EP4121428A1 (en) 2023-01-25
IL294301A (en) 2022-08-01
KR20220155575A (ko) 2022-11-23
WO2021185878A1 (en) 2021-09-23
TW202140466A (zh) 2021-11-01
AU2021238632A1 (en) 2022-07-14
CA3166331A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2022010794A (es) Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).
BR0315315A (pt) Método para tratar, prevenir ou controlar uma sìndrome mielodisplásica, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
IL178591A (en) 4– (Amino) –2– (2,6 – Dioxo (3-piperidyl)) - Isoindulin – 1,3 – Dion for the treatment and management of myelodysplastic syndromes
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
EA200800147A1 (ru) Способ получения олмесартан медоксомила
ZA200605475B (en) Immunomodulatory compounds for the treatment of central nervous system disorders
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
EA201270602A1 (ru) N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
BRPI0413186A (pt) composição de fexofenadina e processo para preparação da mesma
MX2022005371A (es) Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperi din-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
PE20221455A1 (es) Composicion farmaceutica que comprende selexipag
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
MX2018000963A (es) Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol.
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
MX2022011240A (es) Azálidos de urea inmunomoduladores.
CA3156340A1 (en) N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE SUBSTANCE
MX2021013347A (es) Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.
RU2013126798A (ru) Комбинированная терапия дексаметазоном
JP2016537364A5 (es)